SCHEMBL23958129

SCHEMBL23958129

CC(=O)Nc1ccc2nc(Nc3cccnc3)n(-c3ccccc3)c(=O)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.47
▸ MAPT P10636 6/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ G6PD P11413 2/20 0.44
▸ TLR9 Q9NR96 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ PABPC1 P11940 1/20 0.42
▸ CYP11B1 P15538 1/20 0.42
▸ CYP11B2 P19099 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23958215 0.84 MDM2 (0.49) MAPTKDM4EKMT2ASMN1; SMN2ALOX12
SCHEMBL30103264 0.84 MDM2 (0.49) MAPTKDM4EKMT2ASMN1; SMN2ALOX12
SCHEMBL23958217 0.84 MET (0.49) MAPTHSD17B10MAPK1CYP1A2CYP3A4
SCHEMBL23958165 0.82 LRRK2 (0.43) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL23958278 0.82 TUBB4A (0.45) ALDH1A1KMT2AALOX12
SCHEMBL23958265 0.82 PIK3CD (0.46) KMT2AALOX12
SCHEMBL30025728 0.82 TUBB4A (0.45) ALDH1A1KMT2AALOX12
SCHEMBL24110981 0.82 ALOX12 (0.43) MAPTKMT2AALOX12
SCHEMBL23958121 0.82 ALOX12 (0.43) MAPTKMT2AALOX12
SCHEMBL29738614 0.82 PIK3CD (0.46) KMT2AALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-16 — — US disclosed
WO-2021215537-A1 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 (JP) 2021-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE CRKL, CLIC4, CLIC1 NPC1 979/4885MAPT 4749/4885KDM4E 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback